Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox for Iron Overload Post-Allogeneic HCT
NCT00654589Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Serum ferritin values at 52 weeks. Started Feb 2008; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT00654589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00654589.